Next Article in Journal
The UGG Isoacceptor of tRNAPro Is Naturally Prone to Frameshifts
Next Article in Special Issue
Mental Health in Multiple Sclerosis Patients without Limitation of Physical Function: The Role of Physical Activity
Previous Article in Journal
Bacterial Cellulose Production from Industrial Waste and by-Product Streams
Previous Article in Special Issue
Listeria Meningitis Complicating Alemtuzumab Treatment in Multiple Sclerosis—Report of Two Cases
Article Menu
Issue 7 (July) cover image

Export Article

Open AccessReview
Int. J. Mol. Sci. 2015, 16(7), 14850-14865;

Stepchild or Prodigy? Neuroprotection in Multiple Sclerosis (MS) Research

Department of Anatomy and Cell Biology, University of Wuerzburg, Wuerzburg 97070, Germany
Author to whom correspondence should be addressed.
Academic Editors: Christoph Kleinschnitz and Sven Meuth
Received: 30 May 2015 / Revised: 23 June 2015 / Accepted: 26 June 2015 / Published: 1 July 2015
(This article belongs to the Special Issue Advances in Multiple Sclerosis)
Full-Text   |   PDF [8876 KB, uploaded 1 July 2015]   |  


Multiple sclerosis (MS) is an autoimmune disorder of the central nervous system (CNS) and characterized by the infiltration of immune cells, demyelination and axonal loss. Loss of axons and nerve fiber pathology are widely accepted as correlates of neurological disability. Hence, it is surprising that the development of neuroprotective therapies has been neglected for a long time. A reason for this could be the diversity of the underlying mechanisms, complex changes in nerve fiber pathology and the absence of biomarkers and tools to quantify neuroregenerative processes. Present therapeutic strategies are aimed at modulating or suppressing the immune response, but do not primarily attenuate axonal pathology. Yet, target-oriented neuroprotective strategies are essential for the treatment of MS, especially as severe damage of nerve fibers mostly occurs in the course of disease progression and cannot be impeded by immune modulatory drugs. This review shall depict the need for neuroprotective strategies and elucidate difficulties and opportunities. View Full-Text
Keywords: axonal damage; degeneration; multiple sclerosis; neuroprotection; regeneration axonal damage; degeneration; multiple sclerosis; neuroprotection; regeneration

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Rottlaender, A.; Kuerten, S. Stepchild or Prodigy? Neuroprotection in Multiple Sclerosis (MS) Research. Int. J. Mol. Sci. 2015, 16, 14850-14865.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top